Shares of the small-cap, actively traded Ironwood Pharmaceuticals, Inc. IRWD were seeing positive momentum Wednesday on top of the 8.08% gain the stock recorded Tuesday.
What Happened
Ironwood and Allergan plc AGN announced positive topline results from a Phase 3b study evaluating Linzess 290 mcg for multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation, or IBS-C.
The companies said the late-stage study met the primary multicomponent endpoint of the drug, when administered orally once-daily, demonstrating an improvement in overall abdominal symptoms of bloating, pain and discomfort in adult patients with IBS-C compared to placebo.
Linzess also met the secondary endpoints of showing a clinically meaningful response, as defined by the abdominal symptom score responder, of a patient seeing an improvement of at least two points from the baseline in a weekly abdominal score for the last six of the 12 weeks of treatment.
The late-stage study also confirmed the safety of Linzess.
Why It's Important
Linzess, an FDA-approved drug for IBS-C or chronic idiopathic constipation, or IDC, is marketed in the U.S. by Ironwood and Allergan.
About 95% of adults with IBS-C experience bothersome abdominal bloating, pain and/or discomfort, the companies said, citing research estimates. An estimated 13 million adults in the U.S. suffer from IBS-C.
"I believe the data from this LINZESS Phase 3b trial will be very important in helping patients and physicians have a more comprehensive dialogue about the multiple symptoms associated with IBS-C," Lin Chang, professor of medicine at UCLA, said in a statement.
Ironwood shares were up 5.48% at $12.13 at the time of publication Wednesday, while Allergan shares were up 3.49% at $124.87.
Related Links:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
